Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

Following the negative Phase I trial outcome for its autoimmune disease treatment, the company is cutting 73% of jobs.

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...

Saad Z. Usmani, MD, MBA, FACP, discusses how the definition of the transplant-ineligible population for multiple myeloma is evolving while also addressing the challenges of standardizing minimal ...

Team Gleason has expanded its collaboration with Stentrode developer Synchron to help teach people about brain-computer ...

Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK ...